If a molecule of the type the sensor is designed to detect sticks to one of these anchored antibodies, it can also stick to an antibody on one of the free-floating outer channels.
They're trying to figure out whether the problems with torcetrapib come from lowering HDL cholesterol, lowering a particular type of HDL cholesterol, or from some unique characteristic of the torcetrapib molecule itself.